Inflammatory Breast Cancer: The Disease, the Biology, the Treatment

Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer accounting for 2.5% of all breast cancer cases. It is characterized by rapid progression, local and distant metastases, younger age of onset, and lower overall survival compared with other breast cancers. Historically, IBC is a lethal disease with less than a 5% survival rate beyond 5 years when treated with surgery or radiation therapy. Because of its rarity, IBC is often misdiagnosed as mastitis or generalized dermatitis. This review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc.

[1]  S. Merajver,et al.  Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. , 2002, Molecular cancer therapeutics.

[2]  T. Odom-Maryon,et al.  Beyond Palliative Mastectomy in Inflammatory Breast Cancer—A Reassessment of Margin Status , 1999, Annals of Surgical Oncology.

[3]  G J Metzger,et al.  MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x‐ray mammography and palpation , 2001, Journal of magnetic resonance imaging : JMRI.

[4]  S. Romain,et al.  Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition? , 1995, International journal of cancer.

[5]  E. van Marck,et al.  NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation , 2007, British Journal of Cancer.

[6]  P. Levine,et al.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.

[7]  P. Levine,et al.  The epidemiology of inflammatory breast cancer. , 2008, Seminars in oncology.

[8]  S. Steinberg,et al.  Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. , 2007, Radiology.

[9]  David A Mankoff,et al.  Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.

[10]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[11]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[12]  L. Muenz,et al.  Clinical and prognostic features of a rapidly progressing breast cancer in tunisia , 1977, Cancer.

[13]  Y. Yen,et al.  Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. , 2004, Journal of Clinical Oncology.

[14]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[15]  K. Tobias,et al.  Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. , 2009, The Canadian veterinary journal = La revue veterinaire canadienne.

[16]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Á. Balogh,et al.  [Inflammatory cancer of the breast]. , 1979, Orvosi hetilap.

[18]  A. Leitch.  PEAU D'ORANGE IN ACUTE MAMMARY CARCINOMA: ITS CAUSE AND DIAGNOSTIC VALUE. , 1909 .

[19]  S. Merajver,et al.  WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. , 2004, Neoplasia.

[20]  G. Fleming.  Locally Advanced, Locally Recurrent, and Metastatic Breast Cancer , 2003 .

[21]  Min-Ying Su,et al.  Monitoring the Size and Response of Locally Advanced Breast Cancers to Neoadjuvant Chemotherapy (Weekly Paclitaxel and Epirubicin) with Serial Enhanced MRI , 2003, Breast Cancer Research and Treatment.

[22]  F. Bertucci,et al.  Defining the molecular biology of inflammatory breast cancer. , 2008, Seminars in oncology.

[23]  D. Miglioretti,et al.  Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. , 2007, Journal of the National Cancer Institute.

[24]  G. Bonadonna,et al.  Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy , 1976, Cancer.

[25]  J. Siegel.  Inflammatory carcinoma of the breast. , 1952, A.M.A. archives of dermatology and syphilology.

[26]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[27]  A. Buzdar,et al.  Inflammatory breast cancer and body mass index. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Hortobagyi,et al.  Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Bondy,et al.  A Progress Review of the Inflammatory Breast Cancer Registry at the University of Texas M.D. Anderson Cancer Center. , 2009 .

[30]  S. Barsky,et al.  An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. , 2001, Cancer research.

[31]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[32]  O. Nalcioglu,et al.  Inflammatory Breast Cancer After Neoadjuvant Chemotherapy: Can Magnetic Resonance Imaging Precisely Diagnose the Final Pathological Response? , 2008, Annals of Surgical Oncology.

[33]  田崎 信一.  郷に入っては (When in Tunisia) , 2007 .

[34]  G. Cavet,et al.  Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer , 2009, Molecular Cancer Therapeutics.

[35]  Luc Bidaut,et al.  Multisensor Imaging and Virtual Simulation for Assessment, Diagnosis, Therapy Planning, and Navigation , 2001 .

[36]  D. Mankoff,et al.  Evaluation of the Internal Mammary Lymph Nodes by FDG-PET in Locally Advanced Breast Cancer (LABC) , 2004, American journal of clinical oncology.

[37]  G. Hortobagyi,et al.  Disease‐free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy , 2006, Cancer.

[38]  S. Achilefu.  Lighting up Tumors with Receptor-Specific Optical Molecular Probes , 2004, Technology in cancer research & treatment.

[39]  Eric J Feuer,et al.  The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.

[40]  D. Newman.  A System of Operative Surgery , 1910, Bristol Medico-Chirurgical Journal (1883).

[41]  M. Mathieu,et al.  Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance , 1989, International journal of cancer.

[42]  S. Merajver,et al.  Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer , 2009, Clinical Cancer Research.

[43]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  A. Hall,et al.  Rho GTPases and the actin cytoskeleton. , 1998, Science.

[45]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[46]  C. Perez-Mesa,et al.  Inflammatory carcinoma of the breast , 1978, Cancer.

[47]  P. Bonnier,et al.  Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. , 1992, Anticancer research.

[48]  B. Ross,et al.  Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Nola Hylton,et al.  MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. , 2006, Magnetic resonance imaging clinics of North America.

[50]  G. Hortobagyi,et al.  p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[51]  D. Sanders,et al.  Melanoma erysipeloides: inflammatory metastatic melanoma of the skin , 1993, The British journal of dermatology.

[52]  A. Thompson.  Gene expression in human breast cancer , 1991 .

[53]  N Andrieu,et al.  Strong association between c-myb and oestrogen-receptor expression in human breast cancer. , 1990, Oncogene.

[54]  J. Julien,et al.  [Inflammatory cancer of the breast]. , 1987, Presse medicale.

[55]  M. Pollak.  Targeting insulin and insulin-like growth factor signalling in oncology. , 2008, Current opinion in pharmacology.

[56]  S. Teitelbaum,et al.  Inflammatory carcinoma of the breast. A Pathologic Definition , 1974, Cancer.

[57]  S. Swain,et al.  Clinical aspects of inflammatory breast cancer. , 2005, Breast disease.

[58]  G. Hortobagyi,et al.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.

[59]  M. Morrow,et al.  Surgical aspects of inflammatory breast cancer. , 2005, Breast disease.

[60]  J. McMurray,et al.  Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. , 2008, Journal of experimental therapeutics & oncology.

[61]  D. Welch,et al.  Metastamir: the field of metastasis-regulatory microRNA is spreading. , 2009, Cancer research.

[62]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[63]  O. Kallioniemi,et al.  Molecular cytogenetic analysis of 11 new breast cancer cell lines , 1999, British Journal of Cancer.

[64]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  G. Hortobagyi,et al.  Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer , 2008, Clinical Cancer Research.

[66]  Lewis D. Griffin,et al.  Zen and the art of medical image registration: correspondence, homology, and quality , 2003, NeuroImage.

[67]  G. Mann,et al.  Targeting lymphangiogenesis to prevent tumour metastasis , 2006, British Journal of Cancer.

[68]  Selin Carkaci,et al.  Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.

[69]  S. Barsky,et al.  An Intact Overexpressed E-cadherin/α,β-Catenin Axis Characterizes the Lymphovascular Emboli of Inflammatory Breast Carcinoma , 2001 .

[70]  T. Smith,et al.  Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. , 1999, International journal of radiation oncology, biology, physics.

[71]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[72]  L. Bidaut,et al.  Advanced imaging including PET/CT for cardiothoracic surgery. , 2004, Seminars in thoracic and cardiovascular surgery.

[73]  S. Merajver,et al.  Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.

[74]  E K Rowinsky,et al.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. Desilvio,et al.  Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  I. Günhan-Bilgen,et al.  Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. , 2002, Radiology.

[77]  Dmitri Artemov,et al.  Magnetic resonance molecular imaging of the HER-2/neu receptor. , 2003, Cancer research.

[78]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[79]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[80]  G. Fletcher,et al.  Multimodality treatment for inflammatory breast cancer. , 1990, International journal of radiation oncology, biology, physics.

[81]  Jinwoo Cheon,et al.  Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.

[82]  Hideo Nakamura,et al.  Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP‐412 (AV‐412) in mouse xenograft models , 2009, Cancer science.

[83]  P. Rosen,et al.  Inflammatory carcinoma of the breast. , 1938, The Surgical clinics of North America.

[84]  M. Phelps,et al.  18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[85]  G. A. van der Marel,et al.  Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. , 2000, Biochemical pharmacology.

[86]  K. Siziopikou,et al.  Rosen's Breast Pathology , 2009 .

[87]  E. Resetkova.  Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis. , 2008, Seminars in oncology.

[88]  M. Hendrix,et al.  Molecular plasticity of human melanoma cells , 2003, Oncogene.

[89]  D. Hill,et al.  Non-rigid image registration: theory and practice. , 2004, The British journal of radiology.

[90]  Barbara L. Smith,et al.  Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  M. Viergever,et al.  Medical image matching-a review with classification , 1993, IEEE Engineering in Medicine and Biology Magazine.

[92]  C. Chow.  Imaging in inflammatory breast carcinoma. , 2005, Breast disease.

[93]  M. Kurosumi,et al.  Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 , 1999, British Journal of Cancer.

[94]  Ruiz Simón Amparo,et al.  Inflammatory Breast Carcinoma: Pathological or Clinical Entity? , 2000, Breast Cancer Research and Treatment.

[95]  Seigo Nakamura,et al.  Molecular targets for treatment of inflammatory breast cancer , 2009, Nature Reviews Clinical Oncology.

[96]  G. Hortobagyi,et al.  Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. , 2006, Clinical breast cancer.

[97]  P. Goodwin,et al.  Metformin in breast cancer: time for action. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  S. Singletary,et al.  Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma , 1997, Annals of Surgical Oncology.

[99]  Bingshu E. Chen,et al.  Epidemiology of inflammatory breast cancer (IBC). , 2005, Breast disease.

[100]  Kil Woo Lee,et al.  Inflammatory breast cancerImaging findings , 2005 .

[101]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[102]  S. Chung,et al.  Inflammatory breast cancer: imaging findings. , 2005, Clinical imaging.

[103]  M. Wicha,et al.  Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling , 2009, PLoS biology.

[104]  Dockerty Mb,et al.  Inflammatory carcinoma of the breast. , 1948, Surgery, gynecology & obstetrics.

[105]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  S. Singletary,et al.  The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. , 2000, American journal of surgery.

[107]  T. Prochilo,et al.  Long-term results of combined-modality therapy for inflammatory breast carcinoma. , 2004, Clinical breast cancer.

[108]  G. Hortobagyi,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[109]  M. Dewhirst,et al.  Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. , 2003, AJR. American journal of roentgenology.

[110]  Z. Shao,et al.  Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro , 2006, Journal of Cancer Research and Clinical Oncology.

[111]  M. Merino,et al.  The Role of 18F-FDG-PET in the Local/Regional Evaluation of Women with Breast Cancer , 2002, Breast Cancer Research and Treatment.

[112]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[113]  E. Rosenthal,et al.  Use of fluorescent labeled anti–epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts , 2007, Molecular Cancer Therapeutics.

[114]  S. Merajver,et al.  WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer , 2003, Breast Cancer Research.

[115]  M. Rahbar,et al.  Case Control Study of Prognostic Markers and Disease Outcome in Inflammatory Carcinoma Breast: A Unique Clinical Experience , 2001, The breast journal.

[116]  A. Lammertsma,et al.  18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  O. Mawlawi,et al.  Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data , 2009, Journal of Nuclear Medicine.

[118]  G. Fletcher,et al.  Multimodal treatment for inflammatory breast cancer. , 1989, International journal of radiation oncology, biology, physics.

[119]  Yi Xiao,et al.  The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. , 2008, The American journal of pathology.

[120]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[121]  A. Rieber,et al.  MRI of the breast in the differential diagnosis of mastitis versus inflammatory carcinoma and follow-up. , 1997, Journal of computer assisted tomography.

[122]  Robert B Livingston,et al.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[123]  D. Schultz,et al.  Ten-year outcome after combined modality therapy for inflammatory breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[124]  D. Slamon,et al.  Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[126]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[127]  G. Hortobagyi,et al.  Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. , 2004, Clinical breast cancer.

[128]  P. Levine,et al.  Epidemiologic features of rapidly progressing breast cancer in Tunisia , 1980, Cancer.

[129]  M. Dowsett,et al.  High incidence of HER-2 positivity in inflammatory breast cancer. , 2004, Breast.

[130]  David J. Yang,et al.  Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[131]  W. Woodward,et al.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. , 2008, International journal of radiation oncology, biology, physics.

[132]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  Deepa Narayanan,et al.  High‐Resolution Fluorodeoxyglucose Positron Emission Tomography with Compression (“Positron Emission Mammography”) is Highly Accurate in Depicting Primary Breast Cancer , 2006, The breast journal.

[134]  S. Singletary,et al.  Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. , 2000, International journal of radiation oncology, biology, physics.

[135]  R. Mehta.  In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) -> weekly carboplatin and albumin- bound paclitaxel (nab-TC) plus trastuzumab (H) or bevacizumab (B) in patients with large and inflammatory breast cancer (BC): A phase II study , 2007 .

[136]  A. Tucker,et al.  Patterns of breast skin thickness In normal mammograms. , 1982, Clinical radiology.

[137]  W. Anderson,et al.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[139]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[140]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[141]  C. Jaffe.  Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  D. Schaid,et al.  Inflammatory Breast Cancer: Integration of Irradiation, Surgery, and Chemotherapy , 1992, American journal of clinical oncology.

[143]  M. Choueiri,et al.  Inflammatory breast cancer in a male. , 2005, The New Zealand medical journal.

[144]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[145]  T. Delozier,et al.  First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial) , 1999, British Journal of Cancer.

[146]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[147]  G. Hortobagyi,et al.  Paclitaxel in the multimodality treatment for inflammatory breast carcinoma , 2001, Cancer.

[148]  Hisataka Kobayashi,et al.  Inflammatory breast cancer: Vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model , 2003, Breast Cancer Research.

[149]  S. Merajver,et al.  Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-Inflammatory Breast Cancer , 2004, Breast Cancer Research and Treatment.

[150]  G. Hortobagyi,et al.  Inflammatory breast cancer: defining breast magnetic resonance imaging features. , 2009 .

[151]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[152]  P. Dam,et al.  Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling , 2006, Breast Cancer Research and Treatment.

[153]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  S. Hilsenbeck,et al.  Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. , 2003, Clinical breast cancer.

[155]  A. Ahuja,et al.  High resolution sonographic detection of axillary lymph node metastases in breast cancer. , 1996, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[156]  F. Robertson,et al.  Cyclooxygenase-2 gene expression in human breast cancer. , 1997, International journal of oncology.

[157]  S. Saltzstein,et al.  Clinically occult inflammatory carcinoma of the breast , 1974, Cancer.

[158]  T. Iwanaga,et al.  Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. , 2002, Cancer research.

[159]  P. Belli,et al.  Role of magnetic resonance imaging in inflammatory carcinoma of the breast. , 2002, Rays.

[160]  V. Raman,et al.  Real time non‐invasive imaging of receptor–ligand interactions in vivo , 2003, Journal of cellular biochemistry.

[161]  Joachim Böttcher,et al.  Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. , 2008, Academic radiology.

[162]  R. Kreienberg,et al.  Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro , 2005, Angiogenesis.

[163]  L. Peña,et al.  Histological, Immunohistological, and Ultrastructural Description of Vasculogenic Mimicry in Canine Mammary Cancer , 2009, Veterinary pathology.

[164]  À. Camins,et al.  Lymphoma of the Breast: Clinical and Radiologic Features With Pathologic Correlation in 28 Patients , 2002, The breast journal.

[165]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[166]  S. Barsky,et al.  Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo. , 2002, Human gene therapy.

[167]  J. Lewin,et al.  Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin , 2007, Clinical Cancer Research.